Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)

Dianthus Therapeutics has reported Cash & Equivalents over the past 8 years, most recently at $12.0 million for Q2 2025.

  • Quarterly results put Cash & Equivalents at $12.0 million for Q2 2025, down 96.2% from a year ago — trailing twelve months through Jun 2025 was $12.0 million (down 96.2% YoY), and the annual figure for FY2024 was $21.9 million, down 83.42%.
  • Cash & Equivalents for Q2 2025 was $12.0 million at Dianthus Therapeutics, up from $10.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for DNTH hit a ceiling of $329.7 million in Q1 2024 and a floor of $10.1 million in Q1 2025.
  • Median Cash & Equivalents over the past 4 years was $38.6 million (2022), compared with a mean of $89.5 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 1320.49% in 2024 and later plummeted 96.93% in 2025.
  • Dianthus Therapeutics' Cash & Equivalents stood at $15.4 million in 2022, then skyrocketed by 761.21% to $132.3 million in 2023, then plummeted by 83.42% to $21.9 million in 2024, then crashed by 45.54% to $12.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $12.0 million (Q2 2025), $10.1 million (Q1 2025), and $21.9 million (Q4 2024) per Business Quant data.